This article is more than 5 years old. Information may no longer be current.
Macugen launched in Latin America
SAO PAULO, Brazil — A treatment for age-related macular degeneration already marketed in the United States and Europe is now available in Latin America, drug company officials announced here.
Pfizer Ophthalmics formally launched Macugen (pegaptanib sodium injection, Pfizer/OSI Pharmaceuticals) in Latin America during the World Ophthalmology Congress in São Paulo, Brazil, a press release from the company said.
Macugen, which works by fighting vascular endothelial growth factor, is indicated for treatment of the wet form of AMD. Macugen was approved for marketing in the United States in December 2004 and by the European Union in February. According to Pfizer, Macugen has also been approved in Argentina, Brazil, Canada, Peru, Pakistan and the Philippines and has filed for approval applications in 15 other countries. An OSI Pharmaceuticals press release noted that Mexico, Australia and Switzerland are among those 15 countries.